At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,373 enrolled
Drug / intervention
vareniclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ASIA CHOICES CHampix Observational Investigation in the CEssation of Smoking
In Brief
An observational study evaluating varenicline for Smoking Cessation. Completed, enrolled 1,373 participants across 97 sites in 4 countries.
Detailed Summary
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesChina, India, Philippines, South Korea
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartFeb 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedDec 15, 2008
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.5 years ago
Interventions
vareniclinedrug
Champix will be prescribed as per usual practice and at the sole discretion of the physician